References
- https://www.ema.europa.eu/en/news/medicines-containing-nomegestrol-chlormadinone-prac-recommends-new-measures-minimise-risk-meningioma
- Nguyen P, Hoisnard L, Neumann A, et al. Use prolonged use of chlormadinone acetate and risk of meningioma intracranial: a cohort study based on data of the SND. EPI-PHARE, 2021. https://www.epi-phare.fr/app/uploads/2021/04/epiphare_rapport_acetate_chlormadinone_avril-2021-1.pdf
- Nguyen P, Hoisnard L, Neumann A, et al. Use prolonged use of nomegestrol acetate and risk of meningioma intracranial: a cohort study based on data of the SNDS. EPI-PHARE, 2021. https://www.epi-phare.fr/app/uploads/2021/04/epi-phare_rapport_acetate_nomegetrol_avril-2021.pdf
- Hage M, Plesa O, Lemaire I, et al. Estrogen and progesterone therapy and meningiomas. Endocrinology. 2022;163(2):bqab259.
- Maiuri F, Mariniello G, Guadagno E, et al. WHO grade, proliferation index, and progesterone receptor expression are different according to the location of meningioma. Acta Neurochir. 2019;161(12):2553–2561.
- Yang X, Liu F, Zheng J, et al. Relationship between oral contraceptives and the risk of gliomas and meningiomas: a dose-response Meta-analysis and systematic review. World Neurosurg. 2021;147:e148–e162.
- Weill A, Nguyen P, Labidi M, et al. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study. BMJ. 2021;372:n37.
- Gazzeri R, Galarza M, Gazzeri G. Growth of a meningioma in a transsexual patient after estrogen–progestin therapy. N Engl J Med. 2007;357(23):2411–2412.
- Del Savio MC, De Fata R, Facchinetti F, et al. Drospirenone 4 mg-only pill (DOP) in 24 + 4 regimen: a new option for oral contraception. Expert Rev Clin Pharmacol. 2020;13(7):685–694.